Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Legends:
Stock price
1.01
Beta (1.0 Market)
% total return 05/17
Stock
S&P500
YTD
80.00
- -
3Y
-79.77
- -
5Y
-86.95
- -
-3.30EPS Dil.
-1.01P/E
32.49MMarket Cap
Working Capital
FRC
•
in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
21
14
6
Cash, Cash Equivalents & STI
20
13
5
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
7
6
Payables & Accruals
5
7
6
ST Debt
0
0
0
Deferred Revenue
- -
- -
- -
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per ShareRevenue per Share
- -
- -
- -
- -
-7,435.42
-4,670.17
-3,594.06
-1,621.28
-686.88
-212.73
-107.22
-52.30
-18.35
-7.62
-4.34
-4.05
-3.30
Basic EPS, GAAPBasic EPS, GAAP
- -
- -
- -
- -
-6,088.50
-3,341.36
-3,100.82
-1,774.01
-1,033.93
-189.87
-81.19
-39.96
-15.26
-7.06
-4.09
-3.61
-3.04
Free Cash Flow per Basic ShareFree Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per ShareDividend per Share
- -
- -
- -
- -
-15,740.03
-20,138.47
-17,019.66
-7,395.74
-7,178.52
-680.64
-505.08
-206.32
-118.94
-27.90
-24.70
-19.13
-20.15
Book Value per ShareBook Value per Share
- -
- -
- -
- -
3,902.83
4,241.46
8.03
1,133.81
-2.85
105.66
48.40
22.70
8.43
7.65
5.18
1.51
-0.19
Tangible Book Value per ShareTangible Book Value per Share